8th Annual Conference of the British HIV Association 19 – 21 April 2002, University of York, York

Oral Abstracts
O1	CURRENT STATUS OF PATIENTS WHO STARTED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) DURING 1996: A DESCRIPTIVE ANALYSIS OF EUROSIDA PARTICIPANTS BHIVA Conf 2002 Apr 19-21;8:O1 LA Paddam1, AN Phillips1, JD Lundgren2, on behalf of EuroSIDA EuroSIDA patients who started HAART in 1996 seem to be doing well more than 4 years later, despite most being nucleoside reverse transcriptase inhibitor-experienced at the start of HAART. Download Abstract Book 2002
O2	CHANGES IN FACTORS ASSOCIATED WITH HIV SURVIVAL IN A EUROPEAN COHORT OF SEROCONVERTERS BHIVA Conf 2002 Apr 19-21;8:O2 K Bhaskaran on behalf of CASCADE collaboration The initial increase in survival expectations has continued. However, IDUs appear to have worse survival in later calendar periods compared to other exposure groups. Age at SC seems to have less prognostic importance in more recent periods. Download Abstract Book 2002
O3	CHANGING POPULATION COST OF HIV SERVICE PROVISION IN ENGLAND, 1996-2004 BHIVA Conf 2002 Apr 19-21;8:O3 EJ Beck1, A Miners1, G Kinghorn2, S Mandalia1, D Parmar1, M Youle1, M Fisher2, J Innes2, MA Johnson2, AL Pozniak2, A Tang2, IG Williams2, BG Gazzard1 for the NPMS-HHC Steering Group Increased resources are required to maintain current standards of care. New configurations of HIV service delivery should be explored in conjunction with measures to reduce HIV transmission. Download Abstract Book 2002
O4	REACHING PROPOSED TARGETS IN THE NATIONAL SEXUAL HEALTH STRATEGY? HIV TESTING IN GENITOURINARY (GUM) SERVICES BHIVA Conf 2002 Apr 19-21;8:O4 G Arthur1, F Burns1, C Mercer2, D Mercey2 Overall HIV testing rates already exceed the proposed 40% national target for 2004. However, it is of concern that in those groups at higher risk, almost half remain untested. Clinician variation in test uptake suggests that training initiatives may improve test uptake. Download Abstract Book 2002
O5	ACUTE SEXUALLY TRANSMITTED INFECTIONS (STIS) IN HIV-POSITIVE GAY MEN: A CASE FOR ENHANCED SCREENING IN HIV TREATMENT CENTRES BHIVA Conf 2002 Apr 19-21;8:O5 J McSorley More than 1/3 of all HIV-positive gay men attending for routine care underwent an STI screen. A high proportion (1/5) of those screened were diagnosed with an acute STI, of whom the majority had a detectable plasma viral load at the time of diagnosis. There is a need to develop and enhance targeted STI and sexual health services in HIV treatment centres. Download Abstract Book 2002
O6	WILL A SYPHILIS OUTBREAK RESULT IN A SECOND HIV EPIDEMIC? BHIVA Conf 2002 Apr 19-21;8:O6 S Hopkins, C Coleman, J Garvey, F Mulcahy, C Bergin Syphilis increases HIV viral load and is a known factor in HIV acquisition. Additionally, given the high rate of known HIV patients acquiring syphilis (approximately 10% of the clinic HIV MSM cohort), we can expect to see further co-diagnosis in this high-risk group. Download Abstract Book 2002
O7	TRANSMISSION OF DRUG-RESISTANT VIRUS IN PRIMARY HIV-1 INFECTION (PHI) BHIVA Conf 2002 Apr 19-21;8:O7 M Brady, S Fidler, J Clarke, J Weber We report a much lower prevalence of drug-resistant virus in primary infection compared with previous studies. Transmission of drug-resistant virus appears to be an increasing problem and rapid genotypic resistant testing is essential in the context of treating primary HIV-1 infection. Download Abstract Book 2002
O8	MULTIDRUG RESISTANT HIV-1 IN THE SEMEN OF MEN WITH ACUTE SEXUALLY TRANSMITTED INFECTIONS BHIVA Conf 2002 Apr 19-21;8:O8 ST Sadiq1, S Taylor2,3, S Kaye2, J Workman2, P Cane2, J Bennett1, A Copas1, S Drake3, I Weller1, D Pillay In men with sexually transmitted infections, multidrug resistant HIV-1 and high viral loads were detected in the semen of those on suboptimal antiretroviral therapy but not in those on effective antiretroviral therapy. These findings may have important public health implications in both the developed and developing world. Download Abstract Book 2002
O9	SEQUENTIAL TRANSMISSION OF HIV-1 CONTAINING DRUG RESISTANCE-ASSOCIATED MUTATIONS BHIVA Conf 2002 Apr 19-21;8:O9 S Taylor1,2, P Cane1, S. Hue1, L Xu1, T Win3, Y Lie3, N Hellman3, C Petropoulos3, J Workman1, D Ratcliffe1 and D Pillay1 Our data suggest that variants with drug-resistance associated mutations can persist within newly infected individuals, despite intervening antiretroviral therapy and can subsequently be sexually transmitted. Download Abstract Book 2002
O10	RESERVOIRS OF PERSISTENT HIV REPLICATION ARE STABLE IN PATIENTS WITH AN UNDETECTABLE VIRAL LOAD BHIVA Conf 2002 Apr 19-21;8:O10 J Morlese, I Teo, JW Choi, BG Gazzard, S Shaunak The circle assay is a simple method of identifying those patients with persistent viral replication despite an undetectable plasma HIV RNA. 42% of the patients with successful long-term suppression of plasma HIV RNA still had persistent viral replication. New drug combinations and therapeutic approaches are needed for these patients. Download Abstract Book 2002
O11	EVIDENCE OF LOW-LEVEL VIRAL REPLICATION (<50 COPIES/ML) PREDICTS EVENTUAL VIROLOGICAL FAILURE BHIVA Conf 2002 Apr 19-21;8:O11 Y Mazen, AL Pozniak, D Pillay, S Mandalia, A Wildfire, BG Gazzard 59% of all blips are non-repeatable on the same sample. Download Abstract Book 2002
O12	THE PREVALENCE AND DETERMINANTS OF THE K65R MUTATION IN HIV REVERSE TRANSCRIPTASE IN TENOFOVIR NAÏVE PATIENTS BHIVA Conf 2002 Apr 19-21;8:O12 A Winston, S Mandalia, D Pillay, B Gazzard, A Pozniak The presence of K65R is associated with prior abacavir use. Although rare, it is preferentially selected within non-thymidine analogue-containing regimens, compared with concurrent zidovudine or stavudine use, which is associated with emergence of thymidine analogue mutations. Both genetic routes taken may compromise both abacavir and tenofovir activity. Download Abstract Book 2002
O13	INTRADERMAL POLYLACTIC ACID (NEWFILL) FOR TREATMENT OF SEVERE HIV-ASSOCIATED FACIAL LIPOATROPHY BHIVA Conf 2002 Apr 19-21;8:O13 JN Day, A Raabe, A M Shiner, EL Wilkins PLA is a popular treatment among patients with facial lipoatrophy, all perceiving an improvement in their appearance. It is well tolerated, but objective improvement in quality of life has not yet been demonstrated. Download Abstract Book 2002
O14	THE REPRODUCIBILITY OF THREE-DIMENSIONAL (3-D) LASER SURFACE SCANS FOR THE ASSESSMENT OF FACIAL LIPOATROPHY (LA) BHIVA Conf 2002 Apr 19-21;8:O14 P Benn1. C Ruff2, J Cartledge1, V Sauret2, A Copas3, A Linney2, IG Williams3 SG Edwards1 3-D laser surface scans of the face are reproducible in patients with and without LA. They may provide an objective means of monitoring facial LA. Further longitudinal studies are needed. Download Abstract Book 2002
O15	PERINATAL ANTIRETROVIRAL THERAPY: MONO- VERSUS COMBINATION THERAPY AND NEONATAL ANAEMIA BHIVA Conf 2002 Apr 19-21;8:O15 CJ Foster1, I Roberts2, EGH Lyall1 and GP Taylor1,2 Perinatal antiretroviral therapy is highly effective in preventing the vertical transmission of HIV-1 but causes significant reduction in neonatal Hb that, in this cohort, was independent of length of antiretroviral exposure but most marked with ZDVcontaining regimens. Download Abstract Book 2002
O16	MANAGEMENT OF MATERNAL HIV DIAGNOSED LATE IN PREGNANCY BHIVA Conf 2002 Apr 19-21;8:O16 F Lyons, S Hopkins, K Butler, C Bergin, K Butler, F Mulcahy Effective management of HIV-1 infection diagnosed late in pregnancy requires detailed guidelines based on different scenarios. Download Abstract Book 2002
O17	EFAVIRENZ AND NEVIRAPINE: POSSIBLE CANDIDATES FOR THERAPEUTIC DRUG MONITORING (TDM) IN CLINICAL PRACTICE? BHIVA Conf 2002 Apr 19-21;8:O17 SE Gibbons, HE Reynolds, J Lloyd, JF Tjia, SH Khoo, DJ Back The results from our selective TDM data set suggest that for NVP and EFV, plasma concentrations alone are insufficient to account for viral response or the development of toxicity. Full clinical and virological data are essential to interpret TDM results. Download Abstract Book 2002
O18	WHO IS LOST TO FOLLOW UP FROM AN HIV CLINIC AND WHY? BHIVA Conf 2002 Apr 19-21;8:O18 LJ Haddow1, SG Edwards1, K Sinka2, DE Mercey1 While most patients LFU were at no immediate health risk to themselves, it is of concern that some patients had started antiretroviral therapy, some had advanced disease, and opportunities for health promotion were lost. Patient groups of special concern will be discussed. Download Abstract Book 2002
O19	PREDICTING NON-ADHERENCE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART): THE ROLE OF PATIENTS' DOUBTS ABOUT PERSONAL NEED AND CONCERNS ABOUT POTENTIAL ADVERSE EFFECTS BHIVA Conf 2002 Apr 19-21;8:O19 R Horne1, V Cooper1, M Fisher2 This ongoing study shows that beliefs about HAART predict adherence. It suggests that interventions to support adherence will be more effective if they take account of patients' beliefs about HAART as well as the practicalities of taking it. Download Abstract Book 2002
O20	IMPACT OF ANTIRETROVIRAL THERAPY ON HEPATITIS B VIRUS (HBV)-SPECIFIC IMMUNE RESPONSES IN HIV/HBV CO-INFECTED PATIENTS BHIVA Conf 2002 Apr 19-21;8:O20 RM Lascar1, R Johnstone1, A Bertoletti2, RJC Gilson1, MK Maini2 Preliminary results suggest that HBV-specific CTL responses can be restored by HAART in the HBV-immune group. Data will be presented for the HBV chronic carrier group. Download Abstract Book 2002
O21	PRESERVATION OF HIV-1 SPECIFIC T-CELL RESPONSES IS RESTRICTED TO A VERY SMALL SUBSET OF TRUE NON-PROGRESSORS BHIVA Conf 2002 Apr 19-21;8:O21 NA Qazi1, BG Gazzard1, N Imami2 Of the 41 patients defined in the 1996 cohort, 35 had progressed, with 29 now receiving antiretroviral therapy. Of these 29, 23 were started on highly active antiretroviral therapy (HAART) as they fulfilled the BHIVA guidelines of CD4 T-cell count <330 cells/µL and/or viral load >30,000 copies/mL. The remaining six patients developed recurrent infections and were recommended HAART by their regular clinic doctors. The six patients not currently on HAART have been regularly reviewed and show signs of falling CD4 T-cell counts, and are likely to need therapy in due course. By comparison, the six true LTNPs have maintained good HIV-1 specific CD4 T-cell proliferative responses to nef, tat p24 and gp120. Download Abstract Book 2002
O22	EFFECT OF HIV-1 VIRAL LOAD AT THE TIME OF ANTIRETROVIRAL THERAPY INTERRUPTION ON THE DURATION OF HIV-1-SPECIFIC T-CELL RESPONSES BHIVA Conf 2002 Apr 19-21;8:O22 C Burton1, M Nelson2, P Hay3, BG Gazzard2, F Gotch1 and N Imami1 We have previously reported that during interruption of antiretroviral therapy, transient HIV-1-specific responses can be generated in patients with chronic HIV-1 infection, with low-level viral rebounds. Here we report that viral load preceding the interruption has little effect on the generation or duration of HIV-1-specific responses. All responses seen are transient and ablated by the re-emerging virus. Download Abstract Book 2002
O23	THE POTENTIAL FOR IMMUNE RECONSTITUTION IN HIV-INFECTED INDIVIDUALS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) WHO ACHIEVE VIROLOGICAL SUPPRESSION BHIVA Conf 2002 Apr 19-21;8:O23 C Smith, C Sabin, F Lampe, S Madge, M Youle, A Cozzi-Lepri, H Gumley, M Johnson, A Phillips Although the rate of immune recovery starts to slow after 2 years, CD4 counts continue to rise in most patients and CD4 counts begin to return to levels seen in HIV-negative individuals. Download Abstract Book 2002
O24	A RANDOMISED, OPEN-LABEL, PHASE I TRIAL OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) COMBINED WITH INTERLEUKIN-2 (IL-2) AND/OR AN INACTIVATED GP120 DEPLETED HIV-1 IMMUNOGEN (REMUNE) BHIVA Conf 2002 Apr 19-21;8:O24 G Hardy1, N Imami1, A Sullivan1, M Nelson1, C Burton1, J Pido-Lopez1, R Moss2, BG Gazzard1 and F Gotch1 Overall, no differences were seen in the induction of HIV-1 CD4 HTL or CD8 CTL responses between those receiving IL-2 and/or Remune, despite an apparent protective effect against virological events by their combination. Download Abstract Book 2002
O25	MULTICENTRE COHORT STUDY OF TESTICULAR CANCER IN MEN WITH HIV BHIVA Conf 2002 Apr 19-21;8:O25 T Powles1, G Daugaard2, MR Nelson1, T Oliver3, M Fisher4, J Stebbing5, J Anderson3, M Johnson5, BG Gazzard1 and M Bower1 The excess of seminoma supports the findings of large US cohort studies; other series from Europe have suggested an excess of mixed GCT and teratomas. The GCTs in this series present and should be treated as in the HIV-negative population. Chemotherapy and radiotherapy are well tolerated, but adversely affect the CD4 count. Download Abstract Book 2002
O26	CYTOMEGALOVIRUS (CMV) VIRAEMIA IS AN INDEPENDENT PREDICTOR OF DISEASE PROGRESSION AND DEATH IN PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) BHIVA Conf 2002 Apr 19-21;8:O26 JR Deayton, CA Sabin, MA Johnson, VC Emery, PD Griffiths CMV viraemia is independently associated with disease progression and death in the era of HAART and is more strongly correlated with risk of death than CD4 count or HIV load. CMV viraemia appears to be a more sensitive predictor of prognosis than other markers and may thus provide a marker for sustained immune function after HAART. Short-term changes in CMV PCR status are important for prognosis, suggesting that treatment of CMV viraemia should be evaluated in a placebo-controlled trial. Download Abstract Book 2002
O27	NEW RETINAL INFECTIONS IN HIV-POSITIVE PATIENTS IN THE POST-HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) ERA BHIVA Conf 2002 Apr 19-21;8:O27 AA Obi, BG Gazzard, SM Mitchell Despite the increasing availability of HAART, retinal infections continue to occur, with the majority of patients having a new or recent HIV diagnosis. Download Abstract Book 2002
O28	A PROSPECTIVE MULTICENTRE STUDY OF DISCONTINUING PROPHYLAXIS FOR OPPORTUNISTIC INFECTIONS: THE STOPIT STUDY BHIVA Conf 2002 Apr 19-21;8:O28 P Hay1, H Green2, D Dunn2, A Babiker2 on behalf of STOPIT The risk of developing OIs in the absence of prophylaxis is very low provided adequate CD4 count levels are maintained. This study lends support to recommendations that prophylaxis or maintenance for PCP, MAC and CMV is not necessary in the context of HAART. Download Abstract Book 2002
O29	PROGRESSION RATE OF LIVER FIBROSIS IN HIV AND HEPATITIS C VIRUS (HCV) CO-INFECTED PATIENTS BHIVA Conf 2002 Apr 19-21;8:O29 AH Mohsen, S Norris, C Taylor, R Kulasegaram, B Portmann, S Lucas, P Easterbrook, GKT HIV-HCV Collaborative Group HIV/HCV co-infected patients have a more rapid rate of fibrosis progression and higher inflammatory grades than patients infected with HCV only. Download Abstract Book 2002
O30	HIV/HEPATITIS C VIRUS (HCV) CO-INFECTED POPULATION: EARLY OUTCOMES WITH PEGYLATED INTERFERON AND RIBAVIRIN BHIVA Conf 2002 Apr 19-21;8:O30 S Hopkins, F Lyons, F Mulcahy, C Bergin Any patient with Hb <10 g/dL is given erythropoietin (4000 IU subcutaneously weekly). Early response rates are low, primarily due to advanced HIV disease and prolonged HCV infection. Download Abstract Book 2002
Poster Abstracts
P1	CALCULATED 10-YEAR CARDIOVASCULAR RISK IN HIV-INFECTED PATIENTS RECEIVING PROTEASE INHIBITORS BHIVA Conf 2002 Apr 19-21;8:P1 J Whetham, AM Smith, IG Williams 16% of our patient population on a PI-containing regimen had a high 10-year risk of CHD. The contribution of PIassociated metabolic abnormalities to CHD risk is uncertain, as is the impact it has on the incidence of CHD over time compared with a general adult population of the same age range. Clinicians should be aware that national guidelines suggest that individuals with a 10-year risk >15% should be targeted for risk modification. Download Abstract Book 2002
P2	PREVALENCE OF CARDIOVASCULAR DISEASE (CVD) RISK FACTORS IN AN ETHNICALLY DIVERSE HIV-POSITIVE POPULATION BHIVA Conf 2002 Apr 19-21;8:P2 C Hodgson1, L Hodgson2, S Murad1, J Herman1, C Taylor1, D Macallan2, P Easterbrook1 A high proportion of our patients have at least one modifiable CVD risk factor. This highlights the importance of identifying those who may benefit from lifestyle changes. Download Abstract Book 2002
P3	NO EVIDENCE OF HYPERLIPIDAEMIA OR LIPODYSTROPHY WITH NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)-OR NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI)-BASED REGIMENS IN AN ETHNICALLY DIVERSE POPULATION BHIVA Conf 2002 Apr 19-21;8:P3 L Hodgson1, C Hodgson2, S Murad2, J Herman2, C Taylor2, P Easterbrook2, D Macallan1 We confirmed an absence, over the short-term, of lipid or body habitus changes in this ethnically diverse population with non- PI-containing regimens. Download Abstract Book 2002
P4	IDENTIFYING PATIENT GROUPS AT RISK OF DEVELOPING A NEVIRAPINE RASH BHIVA Conf 2002 Apr 19-21;8:P4 BM Clark, A Alonso, FJ Vilar, EGL Wilkins Our study suggests that patients with high viral loads are more likely to develop a rash. In this patient group, therefore, the physician may have to consider alternatives to nevirapine. Download Abstract Book 2002
P5	SEPTRIN HYPERSENSITIVITY (SHS): ANOTHER IMMUNE RECONSTITUTION PHENOMENON? BHIVA Conf 2002 Apr 19-21;8:P5 Z Warwick, C Timaeus, GL Dean, DR Churchill, M Fisher We postulate that the timing alongside HAART introduction, association with virological/immunological response to HAART and atypical/severe ADR features suggest that SHS may represent an immune reconstitution phenomenon. In addition to providing insights into the pathogenesis of ADRs in HIV, this hypothesis requires consideration by clinicians. There is considerable overlap between the SHS features described and those well described with antiretroviral agents (such as abacavir and nonnucleoside reverse transcriptase inhibitors) which, if missed, may result in unnecessary discontinuation of HAART. Download Abstract Book 2002
P6	HEPATIC STEATOSIS AND LACTIC ACIDOSIS IN AN HIV/HEPATITIS C (HCV) CO-INFECTED PATIENT FOLLOWING LIVER TRANSPLANTATION (LTX) BHIVA Conf 2002 Apr 19-21;8:P6 R Parkes1, C McDonald, M Foxton2, B Drejovic3, MR Nelson3, A Knisely2, B Portmann2, N Heaton2, S Norris2, C Taylor1 Hepatic steatosis is a complication of HCV infection. However, in view of lactic acidosis and microvacuolar steatosis in this patient, morbidity cannot be ascribed to HCV disease alone, but also to the effects of HAART. Antiretroviral and immunosuppressive therapy must be selected to minimize liver dysfunction. Download Abstract Book 2002
P7	SHORT-COURSE ANTIRETROVIRAL THERAPY IN PRIMARY HIV INFECTION (PHI) BHIVA Conf 2002 Apr 19-21;8:P7 M Brady1, S Fidler1, A Oxenius2, D Price2, T Zhang2, R Phillips2, J Weber1 Short-course antiretroviral therapy was safe and associated with preserved HIV-specific immune responses. PHI is highly heterogeneous, and a large randomized trial of antiretroviral therapy at PHI is now needed. Download Abstract Book 2002
P8	DURABILITY AND TOLERABILITY OF NEVIRAPINE (NVP)-CONTAINING REGIMENS IN A COHORT OF ANTIRETROVIRAL-NAÏVE HIV-POSITIVE PATIENTS BHIVA Conf 2002 Apr 19-21;8:P8 N Mackie1, CA Sabin2, R Weston1, J Weber1 287 patients were eligible for analysis: 74% were male, 61% Caucasian and 30% black African. Risk factors for infection were: homosexuality (58%), heterosexuality (38%) and intravenous drug use (4%); 8% had co-infection with hepatitis B (HBV) or C (HCV) and 14% had a previous AIDS-defining illness. The median (range) baseline CD4 count and HIV-1 RNA were 200 (0-821) cells/μL and 54,494 (202-500,000) copies/mL. The median (range) follow-up was 18 (0-57) months. Over this time, 16% of patients required a change to the NRTI backbone, and 67/287 (23%) failed therapy for virological (29/67, 43%), toxic (24/67, 36%), death (2/67, 3%) and other (4/67, 18%) reasons. 22/67 (33%) stopped NVP in ≤3 months, due to toxicity, mainly rash (n=16). Only three (one HBV+, one HCV+) experienced hepatotoxicity resulting in cessation of NVP. All significant hepatotoxicity occurred in the first 6 weeks and there were no further discontinuations because of liver problems after this period, even in co-infected patients. No patient stopped NVP for lipodystrophy. The median change in the CD4 count from baseline was 190 (-50 to +940). Download Abstract Book 2002
P9	VIROLOGICAL RESPONSE AND SAFETY OF AMPRENAVIR PLUS LOPINAVIR/RITONAVIR IN HEAVILY PRETREATED PATIENTS BHIVA Conf 2002 Apr 19-21;8:P9 R Shah, S McCormick, R Kulasegaram, W Tong, B Peters In heavily pretreated patients with limited antiretroviral options, an effective, tolerable and safe regimen is required. In our cohort the use of a pharmaco-enhanced amprenavir/lopinavir combination met these requirements in the majority of our patients, and might be an alternative option to mega-highly active antiretroviral therapy or strategic therapeutic interruptions. Download Abstract Book 2002
P10	ANTIRETROVIRAL THERAPY IN SEVERELY IMMUNOCOMPROMISED PATIENTS BHIVA Conf 2002 Apr 19-21;8:P10 S Creighton, SG Edwards, A Copas, CB Taylor Triple therapy reduced death rates 15-fold, doubled the duration of follow-up and significantly improved viral load and CD4. PI-based regimens were as effective as those containing an NNRTI. Download Abstract Book 2002
P11	ASSESSMENT OF PATIENTS' ATTITUDES TOWARDS TAKING TRIZIVIR VERSUS COMBIVIR PLUS ABACAVIR IN THEIR HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) REGIMEN BHIVA Conf 2002 Apr 19-21;8:P11 E Davies, K McCormick, SE Barton There is a lack of adherence data to support the intuitive belief that Trizivir is superior to Combivir/abacavir because of a reduced pill burden. However, this small study demonstrates that the majority of patients preferred Trizivir when given the option. In addition, the use of Combivir/abacavir in a small number of patients previously treated with Trizivir resulted in a reduction in self-reported adherence. Download Abstract Book 2002
P12	ONCE DAILY DOSING OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN EDINBURGH BHIVA Conf 2002 Apr 19-21;8:P12 C Leen, S Morris, A Chiswick, R Brettle Once daily dosing of HAART is effective for some patients. A low rate of discontinuation due to viral rebound was noted. Tolerability remains an issue for patients taking a PI as part of their HAART regimen. New tolerable once daily dosing agents might improve these results further. Download Abstract Book 2002
P13	VIROLOGICAL AND CD4 CELL RESPONSE TO TENOFOVIR-BASED REGIMENS IN HEAVILY EXPERIENCED PATIENTS BHIVA Conf 2002 Apr 19-21;8:P13 BM Clark, EL Wilkins Tenofovir is a valuable drug for use in the treatment of heavily pretreated patients, producing significant falls in the viral load when used with other agents, in particular lopinavir/ritonavir. It is also very well tolerated. Download Abstract Book 2002
P14	NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)-BASED THERAPY FOR THE TREATMENT OF ACUTE AND EARLY HIV-1 INFECTION: CLINICAL ISSUES AND IMMUNOLOGICAL STUDIES BHIVA Conf 2002 Apr 19-21;8:P14 S Portsmouth1, N Imami2, A Pires2, J Hand1, F Gotch2, MR Nelson1, BG Gazzard1 Identifying patients with acute HIV-1 infection is difficult; most start therapy >40 days after infection. The median CD4 change from baseline was 190 (–50, +940) cells/µL. Nonnucleoside reverse transcriptase inhibitor-based combination therapy for early HIV-1 infection is tolerated and effective at controlling HIV-1 viraemia and there is little restoration of HIV-1-specific immunity. Download Abstract Book 2002
P15	HIV-RELATED LUNG CANCER IN THE PRE- AND POST-HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) ERA BHIVA Conf 2002 Apr 19-21;8:P15 T Powles, MR Nelson, S Mandalia, BG Gazzard, M Bower Patients with HIV and lung cancer present with advanced disease and have a poor outcome. This study suggests that the incidence of the disease may be rising in the HAART era, despite improved immune function. Larger, more powerful studies are required to investigate this further. Download Abstract Book 2002
P16	DUODENAL HIV-1 RNA LOAD IS INCREASED IN HIV PATIENTS WITH AN OPPORTUNISTIC INTESTINAL PATHOGEN OR PATHOGEN-NEGATIVE DIARRHOEA BHIVA Conf 2002 Apr 19-21;8:P16 P Hayes, D Datta, Y Miao, BG Gazzard The higher duodenal HIV loads observed in this study in patients with an opportunistic intestinal pathogen may be due to inflammation and immune activation associated with these infections. The intestine may be an important reservoir of HIV during HAART. Download Abstract Book 2002
P17	THE INCIDENCE OF KAPOSI'S SARCOMA (KS) SINCE THE INTRODUCTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART): NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)-BASED REGIMENS PREVENT KS BHIVA Conf 2002 Apr 19-21;8:P17 S Portsmouth, M Bower, S Mandalia, MR Nelson, BG Gazzard Since the introduction of HAART in 1996, the incidence of KS has dropped sharply. Most KS occurs in antiretroviral-naïve patients. Patients developing KS while on HAART are usually experiencing treatment failure. NNRTIs are as effective at preventing KS as PIs are. Download Abstract Book 2002
P18	HIGH PREVALENCE OF HERPES SIMPLEX VIRUS (HSV)-2 INFECTION IN HIV-SEROPOSITIVE PATIENTS IN SOUTH LONDON BHIVA Conf 2002 Apr 19-21;8:P18 M Ramaswamy1, M Smith1, C Taylor2, M Zuckerman1, D Brown3, AM Geretti1,4 HSV-2 seroprevalence is high among HIV-infected individuals in South London, and appears to be influenced by both gender and ethnicity. In the face of increasing risk-taking behaviour among HIV-infected individuals, consideration should be given to screening patients for HSV-2 antibodies, and counselling co-infected patients about HSV-2 ability to increase HIV transmission. Download Abstract Book 2002
P19	CO-INFECTION OF HIV AND HEPATITIS C VIRUS (HCV): RESPONSE TO ANTIRETROVIRAL THERAPY IN TREATMENT-NAÏVE PATIENTS BHIVA Conf 2002 Apr 19-21;8:P19 J Atkinson, RP Brettle, A Wilson Our experience (unlike the Swiss cohort) was that HCV co-infection had no effect on CD4 response in antiretroviral-naïve patients during the first year of therapy. Download Abstract Book 2002
P20	CANCERS OF THE HEAD AND NECK (HNC): A NEW HIV-RELATED TUMOUR? BHIVA Conf 2002 Apr 19-21;8:P20 T Powles1, J Powles2, MR Nelson3, BG Gazzard3, M Bower1 The median age at presentation was 48 years (range 32–53). All seven were homosexual males and two had an AIDS-defining diagnosis before HNC. Six smoked cigarettes. The incidence of HNC was 1.7 (95% confidence interval 0.7-3.6) new cases per 10,000 patientyears, versus 0.6 for the HIV-negative males. Treatment with radiotherapy or chemotherapy was poorly tolerated, with marked mucositis (grade 3–4) and a median fall in the median CD4 cell count from 131 to 77 cells/µL. The median progression-free survival was 7 months (range 3–96+) and the overall median survival was 27 months. Five of the seven died from progressive malignancy and one of HIV. Download Abstract Book 2002
P21	OCCULT HEPATITIS B (HBV) INFECTION IN HIV-INFECTED PATIENTS WITH HEPATITIS BHIVA Conf 2002 Apr 19-21;8:P21 JN Day, A Bonington So-called 'occult' HBV infection is well described in HIVnegative patients. However, the viral load is usually <1000 copies/mL. The implication of these high HBV viral loads in HIV-positive patients is unclear. Routine antibody/antigen tests may not be sufficient to exclude chronic active hepatitis of viral origin in severely immunosuppressed patients. Download Abstract Book 2002
P22	TENOFOVIR IN THE TREATMENT OF INDIVIDUALS CO-INFECTED WITH HIV AND HEPATITIS B (HBV) BHIVA Conf 2002 Apr 19-21;8:P22 MR Nelson1, A Barr1, M Fisher2, BG Gazzard1 Tenofovir has activity against HBV when used in HIVpositive patients. Those who reach criteria for initiation of HIV antiviral therapy with evidence of HBV replication should consider tenofovir as part of their antiviral regimen. The role of dual therapy with tenofovir and 3TC remains unclear. Download Abstract Book 2002
P23	THE TREATMENT OF LUNG CANCER IN THE ERA OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) BHIVA Conf 2002 Apr 19-21;8:P23 T Powles, R Hawkin, P Shah, S Cox, D Sarker, MR Nelson, BG Gazzard, MR Bower All six patients were treated with platinum-based combination chemotherapy using the same protocols that are employed in immunocompetent patients. The actuarial 1-year overall survival is 25% and there is no significant difference in overall survival compared with the non-HIV patients with lung cancer (log rank P=0.43). Lung cancer in HIV-positive patients is not associated with advanced immunosuppression and may be treated in the same fashion as in the general population with similar survival outcomes. Download Abstract Book 2002
P24	NEW RESPIRATORY PATHOGENS IN HIV/HEPATITIS C (HCV) CO-INFECTED PATIENTS BHIVA Conf 2002 Apr 19-21;8:P24 C De Gascun, J Garvey, S Hopkins, F Lyons, F Mulcahy, C Bergin Many HIV-positive patients have Candida spp. isolated on sputum culture, usually regarded as a colonizer or a pharyngeal pathogen. Invasive Candida is more frequent in decompensated liver disease. Download Abstract Book 2002
P25	CANDIDA GLABRATA ARTHRITIS IN A HIV-1 INFECTED FORMER INTRAVENOUS DRUG USER (IDU) BHIVA Conf 2002 Apr 19-21;8:P25 P Coakley, A Holmes, S Hopkins, F Lyons, F Mulcahy, C Bergin A Medline search showed two cases of C. glabrata arthritis and one of a prosthetic hip infection. All cases were HIV-negative and had hospital exposure. The only identifiable risk infections in the present case are HIV infection and former IDU. Download Abstract Book 2002
P26	DIAGNOSTIC YIELD OF STOOL ANALYSIS AND ENDOSCOPY IN HIV POPULATION PRESENTING WITH DIARRHOEA BHIVA Conf 2002 Apr 19-21;8:P26 D Datta, BG Gazzard In our population, stool analysis in HIV patients with higher CD4 count has a low diagnostic yield. With HAART, infectious causes of diarrhoea are probably less important. Upper and lower GI endoscopies with biopsies were useful diagnostic investigations. Download Abstract Book 2002
P27	THE CLINICAL UTILITY OF THERAPEUTIC DRUG MONITORING (TDM) IN THE MANAGEMENT OF PATIENTS RECEIVING INDINAVIR (IDV) AND RITONAVIR (RTV) BHIVA Conf 2002 Apr 19-21;8:P27 SE Gibbons, HE Reynolds, J Lloyd, JF Tjia, SH Khoo, DJ Back From the wide range of IDV/RTV regimens in clinical use in the UK, there is great variability in the resulting plasma concentrations. TDM has a role in identifying those patients with high concentrations and individualizing IDV/RTV regimens. Download Abstract Book 2002
P28	THE PHARMACOKINETIC (PK) INTERACTION OF LOPINAVIR/RITONAVIR (LPV/R) AND AMPRENAVIR (APV) IN CLINICAL PRACTICE BHIVA Conf 2002 Apr 19-21;8:P28 SE Gibbons, HE Reynolds, JF Tjia, J Lloyd, SH Khoo, DJ Back This is a complex PK interaction and the marked interpatient variability highlights the potential importance of TDM. Download Abstract Book 2002
P29	PHARMACOLOGICAL OPTIMIZATION OF PIS AND NNRTIS (POPIN): THE IMPLEMENTATION OF A NURSE-LED THERAPEUTIC DRUG MONITORING (TDM)/ADHERENCE PACKAGE FOR PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) BHIVA Conf 2002 Apr 19-21;8:P29 J Lloyd1, J Sweeney2, P Flegg2, A Bonington3, E Wilkins3, S Gibbons1, DJ Back1, SH Khoo1 The collection of clinical data and timing of samples is frequently suboptimal and varies according to healthcare professional. Adherence should be assessed in all patients receiving TDM. Dedicated personnel are required to provide the level of intervention necessary for TDM. Nurses are well placed to provide such an intervention. The POPIN clinic has been introduced in three centres in the UK to provide a bestpractice model for TDM. Download Abstract Book 2002
P30	EXPERIENCE OF VOLUNTARY NAMED TESTING FOR HIV FOR ANTENATAL PATIENTS IN A NORTH WEST LONDON HOSPITALS NHS TRUST BHIVA Conf 2002 Apr 19-21;8:P30 OI Braithwaite1 , E O'Sullivan1, A Phil-Ebosie2, M Costello1 Testing has been successful in identifying HIV-positive women in the Brent and Harrow area. A proportion of the patients with known HIV disease now feel confident about either starting a family or having more children, knowing that expert care is available. None of the patients diagnosed antenatally opted for termination of pregnancy. Download Abstract Book 2002
P31	LEPTOMENINGEAL INVOLVEMENT IN AIDS-RELATED NON-HODGKIN’S LYMPHOMA BHIVA Conf 2002 Apr 19-21;8:P31 D Sarker, J Lukawska, J Nathan, MR Nelson, BG Gazzard, M Bower Meningeal disease correlates with established risk factors, and prophylaxis in these high-risk groups prevents meningeal relapse in >80%. Download Abstract Book 2002
P32	DRUG INTERACTION BETWEEN NEVIRAPINE (NVP) AND WARFARIN BHIVA Conf 2002 Apr 19-21;8:P32 M Ghanem, PS Allan, A Wade Warfarin is the oral anticoagulant of choice in the UK and many other countries. Cytochrome (CY)P450 2C9 is the main enzyme to catalyse S-warfarin and CYP1A2 and CYP3A4 are the principal enzymes to catalyse R-warfarin. NVP is primarily an inducer of CYP3A4 enzyme and therefore would be expected to interact with warfarin. In view of the current evidence, clinicians should be aware of that interaction. In managing patients, a higher dose of warfarin than usual might be necessary. Changing NVP to other antiretroviral drugs, if possible, might be considered, especially when an INR higher than 2–3 is recommended. Download Abstract Book 2002
P33	HIV AND PREGNANCY: EXPERIENCE IN AN INNER CITY DISTRICT GENERAL HOSPITAL BHIVA Conf 2002 Apr 19-21;8:P33 S Limb1, D Aleksin2, R Edwards2, K Erskine2, J Anderson3 Pregnant women account for an increasing proportion of new HIV diagnoses. The antenatal clinic provides an important front door to HIV services with complex resource and service implications. Download Abstract Book 2002
P34	ANTENATAL HIV TESTING IN ENGLAND: REVIEW OF POLICY, AFRICAN WOMEN'S EXPERIENCES, AFRICANS' DENIAL OF ACCESS TO MEDICAL CARE AND IMPLICATIONS FOR HIV PREVENTION BHIVA Conf 2002 Apr 19-21;8:P34 L Kawonza There is a need for longer-term solutions and clarity of policy in order to achieve effective mother-to-child HIV prevention. There needs to be a clear decision to ensure women are told that they will not be able to access care so that they could decide to take a test or not, knowing those facts. BHIVA as an organization could influence future policies to help improve the situation. Download Abstract Book 2002
P35	SUBSEQUENT HIV TESTING IN CHILDREN OF HIV-POSITIVE MOTHERS BHIVA Conf 2002 Apr 19-21;8:P35 S Vergnano, J Railton, M Sharland The results are encouraging, as 81% of children living in the UK had been tested. In more recent years, the number of children diagnosed late (more than a year from their mothers) have decreased. Children not tested are clustered in a small number of families. To further reduce late diagnosis in children, we proposed to formalize guidelines for the health advisers to ensure that the issue of testing children is raised routinely after maternal diagnosis. Download Abstract Book 2002
P36	HIV DIAGNOSIS IN THE YEAR 2000: ATTITUDES TO HIV AND TESTING. BHIVA Conf 2002 Apr 19-21;8:P36 S Madge1, A Cozzi-Lepri1, T Fernandez1, MA Johnson1, A Johnson2 These patients were from high-risk groups but many had not previously tested, despite good access to medical care. Many expressed strong views. Few differences were seen in late presenters. Download Abstract Book 2002
P37	LIMITED LIVES: EXPERIENCES OF BLACK AFRICAN WOMEN WITH HIV LIVING IN LONDON BHIVA Conf 2002 Apr 19-21;8:P37 J Anderson1, L Doyal2 The policy implications for the future delivery of primary and secondary HIV care and prevention for this group of patients raised by these findings are discussed. Download Abstract Book 2002
P38	TRENDS AND DETERMINANTS OF HIV TESTING IN GENITOURINARY (GUM) CLINICS AND PRIMARY CARE IN ENGLAND, 1990–2000 BHIVA Conf 2002 Apr 19-21;8:P38 T Chadborn, C McGarrigle, K Fenton HIV testing in GUM clinics has increased without a decline in overall prevalence. If there is a shift to increasing HIV testing in primary care, services should be prepared for an increased need for counselling and referral to specialist services, including drug treatment agencies. Download Abstract Book 2002
P39	EVALUATION OF AN HIV TESTING AWARENESS MEDIA CAMPAIGN BHIVA Conf 2002 Apr 19-21;8:P39 PJ Easterbrook1, T Chadborn2, A Boyd1, P Salami3, M Akello4, M Kizairwe5, I Steen1, S Shafi6, AM Murdin-Geretti1, T Leung1, J Mortimer2 There was an increase in the number of HIV tests performed, particularly in heterosexual attendees of STD clinics and GPs in South London following the campaign. Further details of the organization and conduct of the campaign will be presented. Download Abstract Book 2002
P40	COMPARISON OF HIV-POSITIVE NATIONALS VERSUS NONNATIONALS IN IRELAND BHIVA Conf 2002 Apr 19-21;8:P40 N Boyle, O Lesens, F Lyons, F Mulcahy HIV infection in non-nationals accounted for 48% of all new diagnoses in the study period. Most were females, with 28% diagnosed via antenatal testing, indicating a potentially larger pool of hitherto undiagnosed cases in men. Download Abstract Book 2002
P41	PERCEPTIONS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) AMONG HIV-POSITIVE MEN WHO HAVE BEEN RECOMMENDED TREATMENT BHIVA Conf 2002 Apr 19-21;8:P41 V Cooper1, R Horne1, G Gellaitry1, N Lambert1, M Fisher2 This study has improved our understanding of how HAART is perceived by people faced with difficult treatment decisions. It provides an insight into patients' perspectives of HAART, with implications for the development of interventions to provide decision support. Download Abstract Book 2002
P42	IS THE L90M MUTATION SELECTED MORE FREQUENTLY IN NON-B SUBTYPE HIV-1-INFECTED PATIENTS FAILING NELFINAVIR (NFV)-CONTAINING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)? BHIVA Conf 2002 Apr 19-21;8:P42 L Navaratne, W Tong, J Mullen, S O’Shea, G duMont, A de Ruiter, R Kulasegeram In this small observational study of patients failing after NFV therapy alone, L90M was selected at least as frequently as D30N in non-B subtypes. The clinical significance of developing this mutation could result in cross-class resistance to other PIs not previously thought to be associated with the use of NFV as a first-line protease inhibitor. Larger samples are needed to confirm the significance of this important observation. Download Abstract Book 2002
P43	SEROLOGICAL TESTING ALGORITHM FOR RECENT HIV SEROCONVERSION (STARHS) IDENTIFIES A HIGH PROPORTION OF NEWLY DIAGNOSED HIV INFECTIONS AS INCIDENT BHIVA Conf 2002 Apr 19-21;8:P43 GL Dean1, JV Parry2, G Murphy2, M Fisher1 STARHS, as a routine adjunct to HIV antibody testing, assists in the identification of incident infections. It is, however, essential that appropriate clinical information is matched to the STARHS results as reduced antibody levels (secondary to advanced HIV or HAART) may be interpreted incorrectly. Download Abstract Book 2002
P44	PATIENT AND CLINICIAN VARIABILITY IN ASSESSING THE SEVERITY OF FACIAL LIPOATROPHY (LA) BHIVA Conf 2002 Apr 19-21;8:P44 P Benn1, S Edwards1, J Cartledge1, A Copas2, C Ruff3, A Linney3, IG Williams2 There is significant patient/doctor and intra-doctor variability in evaluating the severity of facial LA. An objective reproducible method of assessing facial LA is needed. Download Abstract Book 2002
P45	RETROSPECTIVE AUDIT OF USE OF VIRAL LOAD (VL) TEST BHIVA Conf 2002 Apr 19-21;8:P45 S Dundas, CLS Leen A high proportion (70%) of VL tests were repeated within 90 days. Only 153/1264 were without reason. £91,000 was spent on VL testing, of which £7600 was used inappropriately. Complex management dictates that many patients need more than four VL tests per year. The budget needs to be redressed. Download Abstract Book 2002
P46	THE CREATION OF A LARGE UK-BASED COHORT OF HIV INFECTED INDIVIDUALS: THE SEVEN CENTRE HIV DATABASE PROJECT BHIVA Conf 2002 Apr 19-21;8:P46 C. Sabin, T Hill, for the UK Seven Centre HIV Database Project Steering Committee Once the audit is complete and all data queries resolved, this database will provide a unique opportunity to address many key questions relating to changes in HIV disease, survival and uptake over time in a large UK-based cohort. Correlates of clinical, immunological and virological response to therapy will be assessed. Downloads of data are planned every 6–9 months to ensure that the data set provides timely information on any changes in disease progression. Download Abstract Book 2002
P47	EPIDEMIOLOGY OF HIV-1 SUBTYPES AMONG DIFFERENT ETHNIC GROUPS IN SOUTHEAST LONDON BHIVA Conf 2002 Apr 19-21;8:P47 I Aggarwal, AM Geretti, M Smith, M Zuckerman, S Murad, PJ Easterbrook This preliminary analysis suggests that country of origin and risk group are important in determining local transmission patterns of HIV subtypes among different ethnic groups. Download Abstract Book 2002
P48	HIV SURVEILLANCE IN THE UK: TRENDS OVER TIME BHIVA Conf 2002 Apr 19-21;8:P48 K Sinka, Z Shaheem, A McHenry, J Mortimer, T Chadborn Public Health Laboratory Service AIDS and Sexually Transmitted A marked fall in cases of AIDS and HIV-related deaths followed the widespread use of HAART after 1996. A concurrent steady increase in the number of new diagnoses, with increasing numbers of heterosexually acquired infections from sub-Saharan Africa, means that prevalence has continued to rise. Forecasts anticipate a 47% rise in numbers attending HIV services between 2000 and 2005. Download Abstract Book 2002
P49	EMERGENCE OF CYTOTOXIC T-LYMPHOCYTE (CTL) ESCAPE VIRAL VARIANTS DURING EARLY HIV-1 INFECTION BHIVA Conf 2002 Apr 19-21;8:P49 NA Jones1, X Wei2, M Wong1, P Newton3, D Cornforth3, IG Williams3, GM Shaw2, P Borrow1 In one patient with a high persisting viral load, the HIV-specific CD8 T-cell response was initially mainly directed against immunodominant epitopes in gp160 and gag, then subsequently broadened to recognize epitopes in other viral proteins. Rapid and sequential selection for viral variants able to escape recognition by the initially immunodominant responses. A subdominant response to an epitope in tat was also seen. In a second patient, with a much lower persisting viral load, a broad CD8 response against >30 epitopes in multiple proteins was seen in acute infection. The strongest responses were to epitopes in gp160 and tat. Escape-conferring mutations were selected only in a group of overlapping epitopes in tat. In these patients, sequential selection of CTL escape viral variants was associated with a primary HIV-specific CD8 T-cell response focused on a limited number of viral epitopes and poor control of early virus replication. Download Abstract Book 2002
P50	VARIED AUTOIMMUNE THYROID DISEASE PHENOTYPES IN A COHORT OF IMMUNE RECONSTITUTED HIV PATIENTS BHIVA Conf 2002 Apr 19-21;8:P50 F Chen, S Day, G Sethi, W Tong, R Metcalfe, J Welch, S Edwards, D Lewis, G Scullard, A Weetman, S Robinson, M Kapembwa, A de Ruiter Although data on AITD in HAART-naïve patients are needed, our observations of varied and rare AITD phenotypes, in temporal relation to HAART, appear unlikely to be chance observations. These phenotypes are observed during the phase of naïve CD4 cell expansion, making IR-AITD a plausible phenomenon. Download Abstract Book 2002
P51	TWO-LONG TERMINAL REPEAT (2-LTR) CIRCLES ARE A RELIABLE AND REPRODUCIBLE MEASURE OF RECENT INFECTION EVENTS IN HIV-1-INFECTED PATIENTS BHIVA Conf 2002 Apr 19-21;8:P51 J Morlese, I Teo, JW Choi, BG Gazzard, S Shaunak The median in vivo half-life of 2-LTR circles is 5.7 days versus an in vitro mean half-life of <12 hours. 2-LTR circles may be a measure of persistent viral replication, being labile in vitro and in vivo. Download Abstract Book 2002
P52	RECOMBINANT HUMAN GROWTH HORMONE (RHGH) WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) FOR THE TREATMENT OF HIV-1 HAS BENEFICIAL EFFECTS ON THE IMMUNE SYSTEM BHIVA Conf 2002 Apr 19-21;8:P52 A Pires1, J Pido-Lopez1, GJ Moyle2, BG Gazzard2, F Gotch1 and N Imami1 The use of rhGH appears to have a direct effect on thymic function, promotes thymocyte development, resulting in an increase in naïve T cells, and induces differentiation into functional memory effector T cells. Download Abstract Book 2002
P53	THE IMMUNOLOGICAL EFFECTS OF LIPOSOMAL ANTHRACYCLINE CHEMOTHERAPY AND CONCOMITANT HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) DURING AND AFTER TREATMENT OF HIV-1-RELATED KAPOSI'S SARCOMA (KS) BHIVA Conf 2002 Apr 19-21;8:P53 B Esdale, M Davies, S Portsmouth, D Sarker, MR Nelson, BG Gazzard, M Bower Liposomal anthracycline chemotherapy, given to patients on HAART, does not adversely affect T-lymphocyte subsets or lead to virological failure. Download Abstract Book 2002
P54	HIV-SPECIFIC CD4 T-HELPER RESPONSES IN PATIENTS WITH LONG-TERM NON-PROGRESSION IN HIV INFECTION BHIVA Conf 2002 Apr 19-21;8:P54 M Boaz1, E Sefia1, A Waters2, P Easterbrook2, A Vyakarnam1 HIV-specific CD4 T-cell responses determined by IFN-γ production do not correlate with control of infection. However, levels of HIV-specific CD4 T cells determined by both IFN-γ and IL-2 production, likely memory effector T-cells, do appear to be correlates of long-term non-progression. Download Abstract Book 2002
P55	IMPACT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) ON OPPORTUNISTIC ILLNESSES (OIS) AND INDIVIDUAL COSTS OF HIV SERVICE PROVISION, ENGLAND, 1996–1999 BHIVA Conf 2002 Apr 19-21;8:P55 EJ Beck1, S Mandalia1, D Parmar1, A Miners1, M Youle1, BG Gazzard1, M Fisher2, J Innes2, MA Johnson2, G Kinghorn2, A Pozniak2, A Tang2, IG Williams2, for the NPMS-HHC Steering Group Increased uptake of HAART reduced AIDS-defining OIs and costs of managing AIDS. By reducing HIV associated morbidity and mortality, HAART reduced the need for inpatient services and the cost of treating people with AIDS. Increasing the number of people alive with HIV infection may increase the population costs for HIV care. Download Abstract Book 2002
P56	CLINICAL GOVERNANCE AND THE AUTOPSY IN HIV DISEASE BHIVA Conf 2002 Apr 19-21;8:P56 SB Lucas Much unexpected pathology emerged for feedback to clinicians, often needing extensive histological and other tests. Most HIV-positive autopsies are Coronial, with little limitation on investigations, and families co-operate when approached for permission to study material further. Download Abstract Book 2002
P57	CORRELATION BETWEEN CD4 RESPONSE AND COST OF HOSPITAL TREATMENT IN ANTIRETROVIRAL-NAÏVE HIV-INFECTED PATIENTS ON TRIPLE ANTIRETROVIRAL THERAPY BHIVA Conf 2002 Apr 19-21;8:P57 S Mandalia1, D Parmar1, M Fisher2, A Pozniak2, A Tang2, M Youle1, BG Gazzard1, EJ Beck1 on behalf of the NPMS-HHC Steering Group A strong linear relationship was observed between the CD4 count and the cost of hospital treatment. Cost-efficacy of drugs and requirements for existing or developing new services can be assessed. Download Abstract Book 2002
P58	ROLE OF POSITRON EMISSION TOMOGRAPHY (PET) SCANS IN THE INVESTIGATION OF PEOPLE WITH HIV BHIVA Conf 2002 Apr 19-21;8:P58 C Watson, I Ho Shon, A de Ruiter, M O'Doherty 62% of PET scans resulted in correct or supportive information. In this small group of patients with probable cerebral lymphoma, the results were unhelpful in half. It is possible that the earlier use of PET in patients with fever may point to a site for biopsy and confirm extent of disease. Download Abstract Book 2002
P59	BEHIND THE PHARMACY DOOR: DISPENSARY-BASED CONTRIBUTIONS TO HIV PATIENT CARE BHIVA Conf 2002 Apr 19-21;8:P59 HA Leake Date1, D Godfrey2, on behalf of the HIV Pharmacy Association3 Dispensary-based pharmacy staff have a key role to play as part of the multidisciplinary team in promoting adherence and minimizing ADEs in PWH. The results of this survey can be used to highlight training needs for healthcare professionals and to identify ways of preventing ADEs. They can also help in the planning of future pharmacy services for HIV teams. Download Abstract Book 2002
P60	PAIN MANAGEMENT IN HIV-POSITIVE PATIENTS BHIVA Conf 2002 Apr 19-21;8:P60 DA Aldington1, E Foley2, RJH Baylis1, D Rowen3 Pain appears to be a common and significant symptom in HIV-positive patients but is poorly managed. Protocols to assess and manage pain should be implemented and joint clinics with a pain management team should be considered. Download Abstract Book 2002

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1980, 2002. AEGiS.